PL2861229T3 - Kompozycja farmaceutyczna zawierająca kwas nikotynowy i/lub nikotynamid i/lub tryptofan do pozytywnego wpływu na mikrobiotę jelitową - Google Patents

Kompozycja farmaceutyczna zawierająca kwas nikotynowy i/lub nikotynamid i/lub tryptofan do pozytywnego wpływu na mikrobiotę jelitową

Info

Publication number
PL2861229T3
PL2861229T3 PL13728758T PL13728758T PL2861229T3 PL 2861229 T3 PL2861229 T3 PL 2861229T3 PL 13728758 T PL13728758 T PL 13728758T PL 13728758 T PL13728758 T PL 13728758T PL 2861229 T3 PL2861229 T3 PL 2861229T3
Authority
PL
Poland
Prior art keywords
nicotinamide
tryptophan
pharmaceutical composition
composition containing
nicotinic acid
Prior art date
Application number
PL13728758T
Other languages
English (en)
Inventor
Georg Waetzig
Dirk Seegert
Original Assignee
Conaris Research Institute Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conaris Research Institute Ag filed Critical Conaris Research Institute Ag
Publication of PL2861229T3 publication Critical patent/PL2861229T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PL13728758T 2012-06-15 2013-06-14 Kompozycja farmaceutyczna zawierająca kwas nikotynowy i/lub nikotynamid i/lub tryptofan do pozytywnego wpływu na mikrobiotę jelitową PL2861229T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102012011890 2012-06-15
PCT/EP2013/062363 WO2013186355A1 (en) 2012-06-15 2013-06-14 A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
EP13728758.7A EP2861229B1 (en) 2012-06-15 2013-06-14 A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota

Publications (1)

Publication Number Publication Date
PL2861229T3 true PL2861229T3 (pl) 2021-08-09

Family

ID=47002494

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13728758T PL2861229T3 (pl) 2012-06-15 2013-06-14 Kompozycja farmaceutyczna zawierająca kwas nikotynowy i/lub nikotynamid i/lub tryptofan do pozytywnego wpływu na mikrobiotę jelitową

Country Status (32)

Country Link
US (2) US10426765B2 (pl)
EP (2) EP3831379A1 (pl)
JP (3) JP6855165B2 (pl)
KR (2) KR102211832B1 (pl)
CN (2) CN104363907A (pl)
AR (1) AR091465A1 (pl)
AU (1) AU2013276451B2 (pl)
BR (1) BR112014030835B1 (pl)
CA (1) CA2876540C (pl)
CY (1) CY1123999T1 (pl)
DK (1) DK2861229T3 (pl)
ES (1) ES2859758T3 (pl)
HK (1) HK1204972A1 (pl)
HR (1) HRP20210090T1 (pl)
HU (1) HUE053359T2 (pl)
IL (1) IL236205B (pl)
IN (1) IN2014DN10260A (pl)
JO (1) JO3578B1 (pl)
LT (1) LT2861229T (pl)
MX (1) MX370795B (pl)
NZ (1) NZ702297A (pl)
PH (1) PH12014502744A1 (pl)
PL (1) PL2861229T3 (pl)
PT (1) PT2861229T (pl)
RS (1) RS61288B1 (pl)
RU (1) RU2657797C2 (pl)
SA (1) SA113340643B1 (pl)
SG (1) SG11201408251SA (pl)
SI (1) SI2861229T1 (pl)
TW (1) TWI624260B (pl)
WO (1) WO2013186355A1 (pl)
ZA (1) ZA201408922B (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE053359T2 (hu) 2012-06-15 2021-06-28 Conaris Res Institute Ag Nikotinsavat és/vagy nikotinamidot és/vagy triptofánt tartalmazó gyógyászati készítmény a bél mikrobiótájának pozitív befolyásolására
CA2914261C (en) 2013-06-05 2020-02-11 The University Of British Columbia Anti-fibrogenic compounds, methods and uses thereof
WO2014200347A1 (en) * 2013-06-14 2014-12-18 Ferring B.V. Extended release nicotinamide formulation
EP2884282A1 (en) 2013-12-13 2015-06-17 CONARIS research institute AG Use of tryptophan as a biomarker for patient selection, dosing and therapy monitoring for pharmaceutical compositions targeting the intestinal microbiota in diseases featuring tryptophan deficiency
WO2015086843A2 (en) * 2013-12-13 2015-06-18 Conaris Research Institute Ag A pharmaceutical composition containing nicotinic acid and/or nicotinamide for beneficially influencing blood lipid levels by modifying the intestinal microbiota
MX2016007323A (es) 2013-12-13 2016-09-09 Conaris Res Inst Ag Una composicion farmaceutica que contiene combinaciones de nicotinamida y acido 5-aminosalicilico para influir beneficiosamente en la microflora intestinal y/o para tratar la inflamacion gastrointestinal.
EP3107553B1 (en) * 2014-02-18 2021-12-01 Universitätsklinikum Jena Methods and compositions for intestinal microenvironment transfer
CN106413680A (zh) * 2014-05-12 2017-02-15 荷兰联合利华有限公司 用于诱导抗微生物肽生成的烟酰胺
CN105287561A (zh) * 2015-11-25 2016-02-03 上海交通大学医学院附属瑞金医院 一种治疗溃疡性结肠炎的药物组合物
NZ747149A (en) * 2016-04-14 2024-03-22 Chromadex Inc Use of nicotinamide riboside, nicotinic acid riboside, nicotinamide mononucleotide, and nicotinoyl compound derivatives in infant formula
KR20180135020A (ko) * 2016-04-19 2018-12-19 훼링 비.브이. 니코틴아미드의 경구 약제학적 조성물
CA3021071A1 (en) 2016-04-19 2017-10-26 Ferring B.V. Oral pharmaceutical compositions of mesalazine
CN109718234A (zh) * 2017-10-31 2019-05-07 中国农业大学 L-色氨酸在缓解肠道炎症反应和屏障功能紊乱中的应用
CN108935981A (zh) * 2018-06-05 2018-12-07 西北农林科技大学 围产期奶山羊添加烟酰胺对羔羊糖脂代谢的影响及其机制
EP3925450A4 (en) * 2019-02-12 2022-09-21 Megumi Tanaka FOOD OR DRINK FOR BABIES AND INFANTS, METHOD FOR IMPROVING THE INTESTINAL ENVIRONMENT OF A BABY OR INFANT, AND METHOD FOR BOOSTING THE IMMUNITY OF THE BABY OR INFANT
WO2020196651A1 (ja) * 2019-03-28 2020-10-01 国立大学法人東北大学 がんの予防又は治療剤
CN113398130A (zh) * 2020-03-16 2021-09-17 广州市妇女儿童医疗中心（广州市妇幼保健院、广州市儿童医院、广州市妇婴医院、广州市妇幼保健计划生育服务中心） 烟酰胺用于预防和治疗胃肠道功能紊乱的用途
WO2022112489A1 (en) * 2020-11-27 2022-06-02 Conaris Research Institute Ag Nicotinamide, nicotinamide precursors and nicotinamide metabolites and compositions thereof for reducing the time to resolution of symptoms in patients with covid-19 and other viral infections
TW202308605A (zh) * 2021-07-19 2023-03-01 日商明治控股股份有限公司 用於炎症性腸疾病之預防或改善之組合物、以及用於腸內細菌叢調節之組合物
WO2023187003A1 (en) * 2022-03-30 2023-10-05 Conaris Research Institute Ag Composition comprising nicotinamide, nicotinamide precursors, nicotinamide metabolites or combinations thereof for preventing or reducing one or more post-acute symptoms of infectious diseases

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
DE19524928A1 (de) * 1995-07-08 1997-01-09 Basf Ag Verfahren zur Rektifikation von Gemischen hochsiedender luft- und/oder temperaturempfindlicher Substanzen, die eine hohe Trennleistung erfordern, im Feinvakuum, sowie für dieses Verfahren geeignete Kolonnen
US5846983A (en) * 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5736532A (en) * 1996-02-14 1998-04-07 Furda; Ivan Multifunctional fat absorption and blood cholesterol reducing formulation comprising chitosan
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
AU776952B2 (en) * 1998-12-23 2004-09-30 G.D. Searle Llc Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications
US6713057B1 (en) 1999-02-24 2004-03-30 The Johns Hopkins University Compositions and methods for modulating serum cholesterol
GB0015242D0 (en) 2000-06-22 2000-08-16 Nycomed Amersham Plc Stabiliser for radiopharmaceuticals
WO2002011725A1 (fr) 2000-08-08 2002-02-14 Shionogi & Co., Ltd. Inhibiteurs de production de cytokine inflammatoire
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
US20060264409A1 (en) 2004-01-20 2006-11-23 Harty Richard F Compositions and methods of treatment for inflammatory diseases
CA2553775A1 (en) 2004-01-20 2005-08-11 Richard F. Harty Compositions and methods of treatment for inflammatory diseases
CA2565993C (en) 2004-05-27 2011-08-16 Antibe Therapeutics Inc. Salt of 4-or 5- aminosalicylic acid
US20080020018A1 (en) * 2004-09-27 2008-01-24 Joey Moodley Combination Products
WO2007004613A1 (ja) * 2005-07-01 2007-01-11 Ajinomoto Co., Inc. 炎症性腸疾患治療薬及びＴＮＦ－α産生抑制剤
PL2026651T3 (pl) * 2006-03-08 2013-06-28 Cortria Corp Terapia kombinowana za pomocą nieselektywnych inhibitorów COX dla zapobiegania uszkodzeń żołądka związanych z COX
ITMI20061932A1 (it) 2006-10-09 2008-04-10 Carlo Ghisalberti Complessi a trasferimento di carica per uso medicale
EP1935422A1 (en) * 2006-12-20 2008-06-25 PEJO Iserlohn Heilmittel-und Diät-GmbH & Co.KG Pharmaceutical composition comprising nicotinamide or nicotinic acid
US20090104171A1 (en) * 2007-10-19 2009-04-23 Pardee Joel D Metabolic Enhancement Therapy
EP2276491A4 (en) * 2008-04-25 2011-08-17 Karolinska Inst Innovations Ab NEW THERAPY FOR THE TREATMENT OF IRRITATION SYNDROME
NZ589469A (en) * 2008-05-20 2012-08-31 Cerenis Therapeutics Holding S A Niacin and NSAID combination for reducing niacin-induced flushing
MX2010013169A (es) 2008-06-02 2010-12-21 Reddy S Lab Ltd Formulaciones de niacina de liberacion modificada.
EA022886B1 (ru) 2008-10-03 2016-03-31 Др. Фальк Фарма Гмбх Способ поддержания ремиссии язвенного колита у пациентов
JP2011121889A (ja) 2009-12-09 2011-06-23 En Otsuka Pharmaceutical Co Ltd 炎症性腸疾患用アミノ酸組成物
JP2012102054A (ja) 2010-11-11 2012-05-31 Kyodo Milk Industry Co Ltd 腸内ポリアミン増強剤
WO2012090224A1 (en) 2010-12-29 2012-07-05 Nutracryst Therapeutics Private Limited Novel cocrystals / molecular salts of mesalamine to be used as improved anti-inflammatory drug
HUE053359T2 (hu) 2012-06-15 2021-06-28 Conaris Res Institute Ag Nikotinsavat és/vagy nikotinamidot és/vagy triptofánt tartalmazó gyógyászati készítmény a bél mikrobiótájának pozitív befolyásolására
WO2014200347A1 (en) 2013-06-14 2014-12-18 Ferring B.V. Extended release nicotinamide formulation
KR20180135020A (ko) 2016-04-19 2018-12-19 훼링 비.브이. 니코틴아미드의 경구 약제학적 조성물

Also Published As

Publication number Publication date
BR112014030835A2 (pt) 2017-06-27
HRP20210090T1 (hr) 2021-03-05
EP2861229B1 (en) 2020-12-23
TWI624260B (zh) 2018-05-21
CA2876540A1 (en) 2013-12-19
KR102211832B1 (ko) 2021-02-02
IL236205A0 (en) 2015-01-29
US20150126462A1 (en) 2015-05-07
RU2014148239A (ru) 2016-08-10
KR20150021071A (ko) 2015-02-27
HUE053359T2 (hu) 2021-06-28
ES2859758T3 (es) 2021-10-04
AU2013276451B2 (en) 2018-03-29
BR112014030835B1 (pt) 2022-01-11
JP2022017332A (ja) 2022-01-25
AR091465A1 (es) 2015-02-04
IN2014DN10260A (pl) 2015-08-07
US20200009124A1 (en) 2020-01-09
HK1204972A1 (en) 2015-12-11
EP2861229A1 (en) 2015-04-22
PH12014502744A1 (en) 2015-02-02
RU2657797C2 (ru) 2018-06-15
KR20200011619A (ko) 2020-02-03
IL236205B (en) 2020-02-27
JO3578B1 (ar) 2020-07-05
WO2013186355A1 (en) 2013-12-19
CN104363907A (zh) 2015-02-18
CN108273064A (zh) 2018-07-13
RS61288B1 (sr) 2021-02-26
AU2013276451A1 (en) 2015-01-15
JP2015519388A (ja) 2015-07-09
JP2019069972A (ja) 2019-05-09
LT2861229T (lt) 2021-01-25
TW201400116A (zh) 2014-01-01
CA2876540C (en) 2022-11-29
CY1123999T1 (el) 2022-05-27
SA113340643B1 (ar) 2019-10-06
PT2861229T (pt) 2021-01-05
MX2014015217A (es) 2015-03-05
JP6855165B2 (ja) 2021-04-07
EP3831379A1 (en) 2021-06-09
US10426765B2 (en) 2019-10-01
DK2861229T3 (da) 2021-01-18
MX370795B (es) 2020-01-08
NZ702297A (en) 2016-11-25
SG11201408251SA (en) 2015-01-29
SI2861229T1 (sl) 2021-03-31
ZA201408922B (en) 2016-10-26

Similar Documents

Publication Publication Date Title
HK1204972A1 (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota //
IL230786A0 (en) Heterocyclic derivatives and pharmaceutical drugs
PT3079675T (pt) Uma composição farmacêutica que contém ácido nicotínico e/ou nicotinamida para utilização para influenciar beneficamente os níveis de lípidos no sangue através da modificação da microbiota intestinal
IL256646B (en) History of azaquinazoline carboxamides and pharmaceutical preparations containing them
IL238060B (en) 2-aminopyridine derivatives, their preparation and pharmaceutical compositions containing them
EP2668186A4 (en) PHARMACEUTICAL COMPOSITION WITH PYRIDIDE DERIVATIVES
IL235947A (en) Solid state isonicotinamide history and their medicinal preparations
HK1187336A1 (en) Pharmaceutical composition comprising pyridone derivatives
EP2789607A4 (en) PYRIDONE DERIVATIVE AND MEDICINE CONTAINING THE SAME
ZA201501095B (en) Pyridine derivative and medicine
PL399613A1 (pl) Pochodne estrów diarylowych kwasów 1-aminoalkanofosfonowych, sposób wytwarzania pochodnych estrów diarylowych kwasów 1-aminoalkanofosfonowych oraz ich zastosowanie
HK1203955A1 (zh) 反式- -癸烯酸衍生物及含有其的藥物
IL234614B (en) Pharmaceutical composition and preparation method thereof
EP2930175A4 (en) NOVEL OCTAHYDROPYRIDOQUINAZOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND USES THEREFOR, AND THE DERIVATIVE THEREOF
TH1401007439A (th) องค์ประกอบทางเภสัชกรรมที่มีนิโคตินิกแอซิด และ/หรือ นิโคตินาไมด์ และ/หรือ ทริปโตฟานเพื่อการมีอิทธิพลในด้านบวกต่อจุลชีพประจำถิ่นในลำไส้